

## **Transgene to showcase two technologies at the 3rd World Congress on Bioavailability and Bioequivalence**

Jan 30<sup>th</sup>, 2012

Transgene Biotek is proud to announce that two of their novel and proprietary technologies will be highlighted during the 3rd World Congress on Bioavailability and Bioequivalence, a Pharmaceutical R & D Summit being held from the 26<sup>th</sup> to the 28<sup>th</sup> March, 2012 at the Marriott Convention Centre in Hyderabad, India. The previous World Congress was held in Las Vegas, USA.

One of Transgene's key collaborators, Dr. Gregory Russell-Jones from Australia, has been invited to deliver a Keynote Speech at the World Congress, followed by 2 sessions during the 3 day Congress.

Dr. Russell-Jones has over 50 patents to his credit and has published more than 50 papers in reputed journals. He is a world-renowned scientist in the fields of oral and transdermal delivery of peptides and proteins. In addition, he has worked extensively on the development of vitamin-mediated targeting systems for the detection and treatment of tumours, and is the co-inventor on several ongoing projects in collaboration with Transgene.

The first session he will be presenting is for the "Sustained Release Dosage Forms" track of the Congress, and is on a novel technology developed in collaboration with Transgene that allows for the preparation of oral dosage forms for poorly water-soluble curcuminoids co-formulated with water-soluble peptides and proteins. Studies conducted by Transgene and Dr. Russell-Jones have led to the identification of a novel formulation that can co-deliver curcuminoids, various oil soluble actives and aqueous solutions of peptides and proteins. These formulations have potential application in the treatment of inflammatory conditions such as multiple sclerosis, Crohn's disease, Parkinson's disease, and rheumatoid arthritis.

The second session presented by Dr. Russell-Jones is for the "Transdermal Drug Delivery Systems" track of the Congress, and the topic of discussion is Transgene's promising new technology for the transdermal needle-free delivery of peptides and proteins using water-in-oil micro-emulsions, which provides a novel means for altering the pharmacology of many subcutaneously administered drugs, with the added potential advantage of directly targeting a multitude of skin diseases, such as psoriasis, eczema, rosacea and skin cancer.

Both of these technologies are currently under development at Transgene Biotek Ltd, Hyderabad for a range of applications, and show huge potential for the future.